Regulatory FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares BioPharma DiveIndustry executives can share their views on the national priority program at a June meeting.RegulatoryRead full story pharminent March 24, 2026 BioPharma Dive Industry executives can share their views on the national priority program at a June meeting. Regulatory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit ManagersNext: Immutrin raises $87M to advance drug for progressive heart disease Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
